Gregory Woodhead Selected Research

tilsotolimod

1/2022

Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory Woodhead Research Topics

Disease

2	Neoplasms (Cancer) 01/2022 - 01/2022
2	Pulmonary Embolism 12/2021 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 07/2020
2	Cholecystitis 05/2020 - 08/2019
1	Fibrosis (Cirrhosis) 10/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Gallbladder Diseases (Gall Bladder Disease) 05/2020
1	Hemorrhage 01/2019

Drug/Important Bio-Agent (IBA)

1	HemosiderinIBA 10/2022
1	tilsotolimodIBA 01/2022
1	Toll-Like Receptor 9IBA 01/2022
1	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2021
1	lenvatinibIBA 07/2020

Therapy/Procedure

2	Catheters 12/2021 - 01/2019
2	Therapeutics 12/2021 - 01/2019
2	Cryosurgery 05/2020 - 08/2019
1	Immunotherapy 01/2022
1	Intra-Arterial Injections 01/2022
1	Immunomodulation 01/2022
1	Cholecystostomy 08/2019
1	Patient Readmission 01/2019